Human embryonic stem (hES) cells have the capability of unlimited undifferentiated proliferation, yet maintain the potential to form perhaps any cell type in the body. Based on the high efficiency of the Epstein-Barr virus-based episomal vector in introducing exogenous genes of interest into mammalian cells, we applied this system to hES cells, expecting that this would resolve the problem of poor transfection efficiency existing in current hES cell research. Therefore, the first step was to establish EBNA1-positive hES cells. Using the Fugene 6 transfection reagent, we transfected hES cells with the EBNA1 expression vector and subsequently generated hES cell clones that stably expressed EBNA1 under drug selection. These clones were confirmed to express EBNA1 mRNA by RT-PCR and to express EBNA1 protein by Western blotting. Furthermore, luciferase reporter gene analysis was performed on the EBNA1 clones and revealed that the expressed EBNA1 protein was functional. When the EBNA1-positive cells were injected into severe combined immunodeficient (SCID) mice, they formed teratoma tissues containing all three embryonic germ layers and EBNA1 protein was detected in these teratoma tissues by Western blotting. All the results show that we have successfully created stable EBNA1-hES cells, thus laying a good foundation for further research. Cai-Ping REN et al.: Establishment of Human Embryonic Stem Cell Line Stably Expressing EBNA1 69 http://www.abbs.info; www.blackwellpublishing.com/abbs Acta
Human embryonic stem (hES) cells are derived from the inner cell mass of in vitro human blastocyst stage embryos [1, 2] . They are capable of unlimitedly proliferating in an undifferentiated manner, yet retain the ability to differentiate into extraembryonic tissues and into advanced derivatives of all three embryonic germ layers. hES cells are important tools in developmental studies, drug testing, and drug discovery because of their proliferative and developmental potential. Moreover, hES cells are of great value as an unlimited cell source for transplantation therapies.
Efficient methods for transfecting hES cells are essential for elucidating the basic mechanisms underlying their differentiation into specific lineages. Several methods for the genetic modification of hES cells have now been reported, each having different advantages and disadvantages. A comparison of several commercially available transfection reagents for transfecting foreign genes into hES cells has resulted in a strategy that yields a stable transfection frequency of approximately 1/10 5 cells [3] . These frequencies are adequate for many applications, but preclude specific experiments that require high transfection efficiencies. For example, when transgene expression causes hES cells to differentiate, it is impossible to recover stable hES cell clones, unless some conditional gene expression system is employed. However, when stable transfectants can be obtained at a high frequency, a useful number of transfectants will be obtained for analysis, even if the transgene induces differentiation. For these reasons, some researchers have previously explored the use of lentiviral vectors in hES cells. Lentiviral vectors transduce hES cells with high efficiency [4] (over 90% when a high multiplicity of infection is used), but using them is fairly labor-intensive, their packaging size is limited, and gene silencing or the integration position effect re-Short Communication mains a concern.
Episomal vectors may be more resistant to gene silencing because they are not subject to integration position effects. Epstein-Barr virus (EBV)-based vectors are episomal expression vectors that have been used successfully for stable transfection in many human cells. The 172 kb genome of EBV is maintained extrachromosomally as a multi-copy circular episome in latently infected B lymphocytes. This episome replicates just once each cell cycle and is partitioned faithfully into daughter cells, akin to cellular chromosomes [5] [6] [7] . The synthesis and maintenance of the EBV vectors require a cis-acting element (the latent origin oriP) and a trans-acting protein (EBNA1, the EBV-encoded nuclear antigen 1). oriP contains two essential elements, namely the dyad symmetry (DS) and the family of repeats (FR). The DS seems to function as the replicator of oriP, while the FR provides nuclear retention of oriP plasmids in cells expressing EBNA1. There is much evidence to show that EBNA1 is the only protein required for replication and maintenance of oriP plasmids [8] [9] [10] . In addition to ensuring the long-term persistence of oriP plasmids, EBNA1 also increases transcription from promoters near oriP (or FR) and enhances the nuclear uptake of oriP plasmids by about 100-fold [11] . Both oriP and the EBNA1 gene can be on the same vector, but the stability of the vector will be improved if the EBNA1 gene is integrated into the cellular genome, followed by the introduction of an oriP plasmid. Ramage et al. [12] report that the presence of EBNA1 protein can lead to an increase in transfection frequency (1000-fold) using an oriPbased vector. Additionally, recovery of episomal plasmids from cell lysates is quite easy and efficient [12] . Finally, the ability to introduce very large human genomic DNA fragments (>100 kb) and maintain them as episomes in human cells is one of the significant advantages of EBVbased vectors [13] .
As the first step in establishing an EBV-based system in hES cells, we transfected the EBNA1 expression vector into hES cells and so created stable EBNA1 hES cell lines under drug selection for a prolonged culture period. We also demonstrated that EBNA1 did not interfere with hES cells and stable expression could be maintained during the differentiation of hES cells.
Materials and Methods
Materials H9 hES cells [1] , which meet the NIH's criteria, were provided by Dr. J. A. Thomson from WiCell Research Institute (Madison, USA), while mouse embryonic fibroblasts (MEFs) were prepared from 13-day mouse embryos. The Burkitt's lymphoma cell line (Raji) came from our laboratory. The pEB plasmid was a gift from Dr. D. W. Dave from Roslin Institute (Edinburgh, UK) [12] . It contained the PGK promoter, EBNA1 cDNA fragment, the encephalo-myocarditis virus (EMCV)-internal ribosome entry site (IRES), neo R , etc. (Fig. 1) . The 985 and 1013 plasmids were generously provided by Dr. B. Sugden from the University of Wisconsin (Madison, USA). The 985 plasmid contained the FR-Tk promoter-luciferase while the 1013 plasmid only contained the Tk promoter-luciferase. Their sequences are available at http://mcardle.oncology. wisc.edu/sugden/. All reagents and chemicals were from Gibco BRL (New York, USA) or Sigma Chemical (St. Louis, USA), unless otherwise stated.
Cell culture
H9 hES cells were grown in hES cell medium consisting of DMEM/F12, supplemented with 20% knockout serum replacement, 1 mM L-glutamine, 0.1 mM MEM non-essential amino acids, 4 ng/ml basic fibroblast growth factor (bFGF) and 0.1 mM β-mercaptoethanol, in a humidified 37 °C incubator with 5% CO 2 , and co-cultured with MEFs at 7.5×10 4 [14] or on matrigel (BD, Bedford, USA) to maintain their undifferentiated state as described previously [15] . The Raji cells were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum.
Transfection and selection
Transfections were performed on matrigel-coated 6well plates using the Fugene 6 transfection reagent (Roche,
Fig. 1 Schematic map of the pEB plasmid
The pEB plasmid contained the PGK promoter, EBNA1 cDNA fragment, the EMCV-internal ribosome entry site (IRES), neo R , β-globin intron, SV40 polyA, 6-16 enhancer, etc..
Basel, Switzerland), as described by the manufacturer. Transfected H9 hES cells were kept for 6 h, and then the Fugene 6-DNA complex was removed. Two days after transfection, 100 µg/ml of G418 (before the transfections, we drew a killing curve of G418 to untransfected hES cells and found that the optimal concentration of G418 was about 100 µg/ml) was added to the growth medium, allowing the selective propagation of transfected cells in the culture. By day 14, neo-resistant colonies appeared. Single transgenic colonies were isolated by a micropipette, dissociated into small clumps of cells and transferred into 4-well plates coated with matrigel. The cells proliferated continuously in the presence of G418 and formed a large number of expanding undifferentiated colonies.
EBNA1 expression analysis
RT-PCR The total RNA was isolated from G418-resistant H9 hES cells with Trizol reagent and then subjected to DNase I treatment at 37 °C for 1 h to remove the residual genomic DNA. Then 4 µl of digested RNA was used for reverse transcription (RT) reactions using a reverse transcription system (Promega, Madison, USA). One-tenth of the RT mixture was placed in a total volume of 50 µl containing 1.5 mM MgCl 2 , 1×PCR buffer, 0.2 mM deoxyribonucleotide triphosphates (dNTPs), 10 pM each of the two EBNA1 primers or GAPDH primers [12] and 2 units of Taq DNA polymerase. The PCR parameters were as follows: after denaturation at 94 °C for 5 min, 35 cycles were performed (94 °C for 45 s, 60 °C for 45 s and 72 °C for 45 s), followed by extension at 72 °C for 10 min. One-fifth of the PCR mixture was electrophoresed on 1.5% agarose gel. Western blotting Extracts from hES cells/Raji cells and teratoma/lyphoma tissues were first prepared. Briefly, hES cells or Raji cells were lysed in the lysis buffer (50 mM Tris, 1 mM EDTA, 150 mM NaCl, 5 mM dithiothreitol, 2% SDS) containing 2 µg/ml leupeptin, 2 µg/ml aprotinin and 100 µg/ml phenyl-methylsulphonyl fluoride (PMSF) and whole cell lysates were obtained after removing the insoluble debris. The teratoma/lymphoma tissues were homogenized in the homogenization buffer (50 mM Tris, 10 mM EDTA, 150 mM NaCl, 0.1% Tween-20, 0.1% SDS, 25 mM Bicine) containing 2 µg/ml leupeptin, 2 µg/ml aprotinin and 100 µg/ml PMSF and centrifugated to collect supernatant lyastes. The concentration of protein was determined by a BCA protein assay kit (Pierce, Rockford, USA). The total protein extracted from EBNA1 cells (100 µg) or teratoma tissues (80 µg) was separated on an 8% polyacrylamide gel and transferred to a nitrocellulose membrane. The membrane was blocked with 5% skimmed milk in TBST (1×Tris buffered saline, 0.1% Tween-20) overnight. The primary antibodies used in this assay were a 1:800 dilution of monoclonal anti-EBNA1 (ABI, Columbia, USA) and a 1:4000 dilution of monoclonal antiβ-actin (Sigma) as a control. The secondary antibody was a 1:1000 dilution of peroxidase conjugated anti-mouse antibody (Amersham, Piscataway, USA). Finally, the membrane was developed using enhanced chemiluminescence (ECL kit, Pierce, Rockford, USA).
Luciferase reporter gene analysis to detect functional EBNA1 protein
Transient transfection was performed in six different EBNA1 hES cell clones on matrigel-coated 6-well plates using the Fugene 6 transfection reagent according to the manufacturer's instructions. Each EBNA1 hES cell clone was transfected with the 985 or 1013 plasmid in parallel, and each transfection was performed in triplicate. At 48 h post-transfection, the transfected cells were collected for the enzymatic activity assay. The cell extracts were prepared with a luciferase assay system (Promega) as described by the manufacturer. Measurements of luciferase activity on three separate transfections were taken in triplicate using a liquid scintillation spectrometer (Beckman, Fullerton, USA). The amount of protein in the lysate was determined by the BCA protein assay kit.
Teratoma formation
EBNA1 + H9 cells from about 60% confluent 6-well plates were injected into the rear leg muscles of severe combined immunodeficient (SCID) male mice aged 4 weeks. Six to eight weeks after injection, the resulting teratomas were examined histologically or by Western blotting. SCID mice were also injected with 1×10 8 Raji cells and the resulting lymphoma was examined in the same way.
Results
H9 hES cells grown on matrigel in the presence of mouse embryonic fibroblast-conditioned medium (CM) were transfected with the pEB plasmid and selected for stable EBNA1 expression clones with 100 µg/ml G418. Nineteen individual colonies were picked and grown in the medium containing G418 for 12 weeks. The morphology of the EBNA1 + H9 cells was seemingly identical to that of non-transfected H9 cells: The cells had high nucleus to cytoplasm ratios, had prominent nucleoli and formed large tightly compacted multicellular colonies (Fig. 2) . There was no obvious change in growth characteristics of http://www.abbs.info; www.blackwellpublishing.com/abbs EBNA1 + hES cells compared with the parental hES cells.
Subsequently, we further identified the EBNA1 + H9 cells and found that the cells retained an undifferentiated hES cell phenotype (SSEA3 + , SSEA-4 + , TRA-1-61 + , TRA-1-80 + , AKP + , OCT4 + ), and had the ability to differentiate judged by the formation of embryoid bodies in vitro and the formation of teratoma tissues in vivo (data not shown).
With the help of the EMCV-IRES, the EBNA1 and neo R genes can be translated from a common dicistronic mRNA under the control of the PGK promoter. Therefore, G418 resistance should be coupled with the expression of EBNA1, facilitating identification of positive clones. Herein, the total RNA of the clones was isolated and analyzed for EBNA1 mRNA expression. Before DNase I treatment, PCR products of EBNA1 could be seen in most RNA samples, while no DNA band could be seen in any RNA samples after digestion with DNase I (data not shown), so the DNase I treatment was necessary and efficient. As the loading control, the expected GAPDH (212 bp) could be seen in all samples tested, including the untransfected H9 cells [ Fig. 3(A) ]. The expected EBNA1 (244 bp) was found in all selected clones [ Fig. 3(B) ]. To confirm EBNA1 protein expression, Western blotting was performed. The expected 87 kD wild-type EBNA1 protein was detected in each clone. The Raji cells were used as a positive control for the mouse anti-EBNA1 antibody tested and the expected 72 kD Raji-form EBNA1 was also detected [ Fig. 3(C) ].
Luciferase assay results showed that the luciferase activity in 985-transfected EBNA1 clones were about 10 to 30 folds of that in EBNA1 clones transfected with the 1013 plasmid, indicating that EBNA1 protein was functional and could bind to the FR element in the 985 plasmid, inducing a higher level of transcription of luciferase (Fig.  4) .
The developmental potential and continuing EBNA1 expression of stably transfected H9 clones were tested during differentiation in the teratomas. Six to eight weeks after injection, all SCID mice produced teratomas. All teratomas had tissues that were typically represented at the same point in time as the teratomas derived from nontransfected hES cells, including the neural epithelium, cartilage, and gut epithelium (data not shown). Western Fig. 2 The morphology of the EBNA1 + H9 cells
The cells had high nucleus to cytoplasm ratios, had prominent nucleoli and formed large tightly compacted multicellular colonies. blotting (Fig. 5) demonstrated continuing EBNA1 protein expression in teratomas. sive packaging procedures make EBV vectors particularly attractive. Furthermore, EBNA1 can increase transfection frequencies (1000-fold) of oriP vectors [12] and enhance expression of the cloned gene by 100-fold in some cell lines [11] without eliciting a cellular immune response in the host, as it can bypass the processing required for presentation of its antigens on MHC class I molecules. The EBV replicon has been used to deliver the cystic fibrosis transmembrane conductance regulator (CFTR) gene to transformed human airway epithelial cells defective in cAMP-dependent chloride transport [17] and to target therapeutic agents at EBV-related tumor cells [18] . Obviously, the EBV replicon can also be applied to gene expression in mammalian cells in culture. It can be used to study the function of genes, the transcription of different promoters and to compensate for defects in recipient cells.
Fig. 3 EBNA1 expression in different EBNA1 clones
Since hES cells were first isolated, much progress in this field has been achieved. However, compared with widely used cell lines, it is difficult to transfect hES cells with general methods, including direct microinjection, electroporation, "biolistic bombardment" or "gene gun" technology, CaPO 4 precipitation, and using liposome reagents such as Lipofectamine 2000 (Gibco BRL, New York, USA), Transit IT-LT1, Transit IT-LT2, Transit IT-100 (Mirus, Madison, USA), SuperFect (Qiagen, Hilden, Germany), etc.. The poor transfection efficiency hampers the study of hES cells; thus, establishing an efficient gene delivery system becomes very desirable. Due to the successful application of the EBV replicon in other cell lines, we tried to develop this system for hES cells. Therefore, we decided to establish stable EBNA1 expression in hES cells as the first step toward setting up an EBV-based vector system.
In this experiment, we have successfully established stable EBNA1 + hES cells, which have been confirmed by RT-PCR and Western blotting. The EBNA1 + hES cells still display several key stem cell characteristics identical to the parental hES cells. Further luciferase assays indicate that the EBNA1 protein is functional and can bind to the FR element in the 985 plasmid, inducing cells with a higher level of luciferase transcription (10-to 30-fold) compared with the EBNA1 + cells transfected by the 1013 plasmid. The developmental potential and continued EBNA-1 expression in transfected H9 cells have been confirmed by teratoma formation and Western blotting. The process for establishing an EBV-based vector system in hES cells is underway. We believe that the first trial of EBV-based shuttle vectors in hES cells will lead to a very useful system for efficient gene transfection, expression cloning and homologous recombination in hES cells, which may be an
Discussion
Eukaryotic viral vectors have played an important role in the expression and analysis of genes. These vectors can be categorized as freely replicating (episomal) plasmids and non-replicating (integrating) vectors [16] . Nonreplicating vectors include derivatives of retroviruses, adenoviruses, adeno-associated viruses and papovaviruses, and they have been used widely in gene therapy, but there are several problems with such viral systems. For example, their integration into host chromosomes is subject to the integration position effect, a phenomenon in which the transcription of the integrated gene is affected by its integration site, and this may result in no transcription, downtranscription or a secondary tumor if the retrovirus integrates into a transcriptionally silent region of chromatin or before a proto-oncogene. Although there is a report [4] demonstrating that lentiviral vectors transfect hES cells efficiently and maintain long-term expression of transgenes, integration position effects remain a concern for these vectors, and the packaging size limits the utilization of these vectors for some specific applications. EBV-based shuttle vectors are the most commonly used episomal vectors at present, as the EBV replicon, consisting of EBV oriP and EBNA1, confers upon the vectors their unique ability to be maintained as stable, freely replicating plasmids. Since they are episomal, EBV vectors should eliminate the effects of integration position and prevent insertional mutagenesis. In addition, the potentially large DNA insert size (up to 720 kb has been reported, using a hybrid YAC/ EBV vector in human cells), the ease of recovering these shuttle vectors from E. coli, and the lack of labor inten-
Fig. 5
Detection of EBNA1 protein expression in teratomas by Western blotting 1, teratomas derived from non-transfected H9 cells; 2, lymphoma derived from Raji cells; 3-8, teratomas derived from different EBNA1 clones. β-actin was used as a loading control.
http://www.abbs.info; www.blackwellpublishing.com/abbs important step toward developing valuable applications for hES cells.
